Prolonged and profound analgesia, sedation and ventilatory depression have been reported in patients suffering from renal failure and receiving parenteral doses of morphine [1] [2] [3] . Our previous studies suggested altered kinetics of morphine in anaesthetized patients receiving the opioid as part of a balanced anaesthetic technique for renal transplant surgery [4] . On the other hand, Aitkenhead and colleagues [5] and Woolner and colleagues [6] reported no alteration in parent drug disposition when i.v. morphine was administered to awake individuals with chronic renal failure. More recently, using a double radioimmunoassy technique, Chauvin and colleagues [7] reported unaltered morphine disposition in anaesthetized uraemic patients undergoing surgery for arterio-venous fistula formation. However, these authors did not assay the two glucuronides of morphine separately.
SUMMARY
anaesthetized patients, and in patients with renal failure undergoing renal transplanation. The use of three separate antisera has allowed estimation of plasma concentrations of morphine, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G).
PATIENTS AND METHODS
The disposition of morphine was investigated in 14 patients, who gave their informed consent to the studies which were approved by the local research Ethics Committee.
Nine patients (four female; ages 19-48 yr, weights 46.8-70 kg) were studied while undergoing renal transplantation. Concurrent medication, including antihypertensive and anti-anginal drugs, was continued up to the morning of surgery, and additional drugs were given with premedication where appropriate. All the patients had undergone haemodialysis within the previous 6-20 h.
Patients were premedicated with oral diazepam 10 mg given 2 h before anaesthesia. Sleep was induced with thiopentone 3-4 mg kg" 1 , and the trachea intubated after neuromuscular blockade was produced with vecuronium 0.1 mg kg"
1 . Anaesthesia was maintained with nitrous oxide in oxygen supplemented with enflurane (up to 0.8 % inspired concentration).
Following the onset of stable anaesthesia, morphine sulphate pentahydrate 10 mg in normal saline 10 ml (morphine 26.4 umol) was injected into a flowing peripheral infusion over 30 s. Venous samples (from a central venous catheter) were collected before induction of anaesthesia, at 1, 2, 5, 10, 15, 30, 45, 60, 90, 120, 180 min and at appropriate times to 1440 min after i.v. injection of morphine. Blood samples were collected into tubes containing lithium heparin, plasma separated by centrifugation, and stored at -20 °C until analysis. Samples were assayed for morphine and its two glucuronides using three separate antisera under optimum conditions [9] .
During operation, patients received crystalloid infusions (sodium chloride 0.154 mol litre" 1 and 5 % dextrose) and plasma substitutes (Haemaccel) to maintain a central venous pressure of 10-12 cm H 2 O. Arterial pressure, heart rate and electrocardiogram were monitored continuously. Immunosuppression was provided by cyclosporin, azathioprine and hydrocortisone.
Data were obtained from five healthy anaesthetized patients (two female; ages 16-55 yr) undergoing elective surgery for ligation of a cerebral aneurysm following subarachnoid haemorrhage. All patients were normotensive at the time of surgery; intraoperative hypotension for application of the clip to the neck of the aneurysm did not exceed a systolic arterial pressure of 80 mm Hg. Premedication and anaesthetic management were similar to those detailed for the renal transplant patients. Morphine sulphate pentahydrate 10 mg was administered when stable anaesthesia had been achieved, and blood sampling was continued to 1440 min.
Data analysis
Kinetic parameters were calculated using a model-independent method. The terminal or elimination half-life was determined by nonlinear regression analysis. The area under the concentration-time curve (AUC) and its first moment (AUMC) were derived using the linear trapezoidal method, and hence allowed calculation of the volume of distribution at steady state (Fd ss ), systemic clearance (C/ P ), and mean residence time (MRT).
Data within the two groups were compared using the Mann-Whitney U test. P < 0.05 was considered significant.
RESULTS
The conduct of anaesthesia was uneventful in all patients. Six of the transplant patients were receiving beta-adrenoceptor blocking drugs. The preoperative haemoglobin, plasma urea and creatinine concentrations in the transplant patients were in the ranges 5.8-10.9 g dl" 1 , 9.0-33.9 mmol litre" 1 and 466-911 umol litre" 1 , respectively. Immediate postoperative creatinine clearances in the transplant patients were between 36 and 138 ml min" However, there were differences in die peak concentration (C max ) and time to this peak (T max ) for the two glucuronide metabolites in the two patient groups (table II) . Peak concentrations of M3G ranged between 243 and 447 nmol litre" 1 in the healthy patients with T max between 30 and 90 min. In the recipients of renal transplants, C m3X was 720-1243 nmol litre" 1 and T max 60-240 min (P = 0.001 and 0.01, respectively). Similar differences existed for M6G, with peak concentrations of 21-112 nmol litre" 1 in the healthy group, and 50-252 nmol litre" 1 in the transplant patients (P = 0.02). There were no differences in the T" max ranges for M6G.
However, the AUC (0-1440 min) for M3G and M6G were significantly greater in those patients undergoing renal transplanation (P < 0.001) (table II, fig. 1 ). There was also a significantly greater value for the ratio AUC morphine-6-glucuronide/AUC morphine in the renal transplant patients (P < 0.02). In the nine patients with renal failure, there was no significant correlation (r = 0.264) between this ratio and immediate graft function expressed as the 24-h creatinine clearance.
The estimated half-lives in the transplant patients were 304-918 min for M3G and 217-898 min for M6G, compared with 173-324 min and 104-127 min in the healthy anaesthetized patients.
DISCUSSION
The disposition of morphine in renal failure patients undergoing transplantation was not significantly different from that in healthy anaesthetized patients, with the exception of a decrease in the volume of distribution at steady state (Fd ss ).
This difference was observed also by Aitkenhead and colleagues in awake subjects [5] , and by Chauvin and colleagues [7] in anaesthetized patients, in whom morphine concentrations were assayed by HPLC and RIA, respectively. A considerable variability in morphine kinetics in healthy anaesthetized patients has been reported [10] [11] [12] [13] . This may relate to many factors such as study design, patient age and sex, anaesthetic technique, concurrent therapy, duration of sampling and assay methodology [14] .
Comparing the mean data for healthy anaesthetized patients from the present study and those from Chauvin [7] , the coefficients of variation for elimination half-life, clearance and apparent volume of distribution at steady state range between 20 and 30%, with no difference between the two studies. A similarly wide dispersion of data in both healthy and renal failure patients can be seen in the study of Aitkenhead and colleagues [5] . In the presence of renal failure, other factors may also interplay; these include a reduced total body water secondary to haemodialysis, and altered protein binding or plasma albumin concentrations.
Comparison of the data for healthy patients in this study and those for the anaesthetized group in the accompanying publication [15] show a longer elimination half-life and greater volume of distribution. This may be explained by the short sampling period in the previous study (180 min compared with 24 h), leading to an underestimation of the terminal half-life. Why do these results differ from our earlier data [4] ? Studies of the specificity of the RIA used in that paper reported a 1 % molar cross reactivity of the antiserum to morphine-3-glucuronide (the principal metabolite of morphine) and a 0.3% cross reactivity to normorphine [13] . Antisera produced by haptenization through 6-hemisuccinyl morphine also demonstrate significant cross reactivity to morphine-6-glucuronide. Boerner, Abbott and Roe [16] indicated a ratio of 100:1 for morphine-3-glucuronide to morphine-6-glucuronide in the urine of post-addict males. However, Svensson and colleagues have demonstrated greater concentrations of M6G-approximately 10% of M3G during chronic oral medication with morphine [17] . This is also in agreement with our own data following i.v. administration [9] . Hence our earlier morphine kinetics in patients with renal failure were inaccurate because of simultaneous measurement of both morphine and morphine-6-glucuronide [4] .
Other data showing increased concentrations of M3G and M6G in patients with chronic renal failure have been reported [3, 18] , in addition to altered kinetics of M6G when given i.v. to patients with renal failure compared with healthy volunteers [19] . Both of the studies reporting the disposition of morphine and its metabolites in renal failure [3, 18] indicated half-lives for M3G of 14.5-136 h, and M6G 38-103 h. Compared with these other reports, the shorter half-lives in our transplanted group may reflect restoration towards normal renal function that occurs following revascularization of the grafted kidney.
Morphine-6-glucuronide has been shown to be analgesically active when administered intracerebrally to rats, and to exhibit avid binding to opioid receptors in bovine brain [20] [21] [22] [23] . In a preliminary study in man, Osborne [19] has reported that 1 mg of M6G provided analgesia lasting for 1-7 h. The increased peak concentrations and AUC for M6G in the patients with renal failure may be important in causing the enhanced clinical effects attributed to the parent opioid. Although the glucuronide metabolites are more polar and less lipid soluble than the parent compound, and hence show only slow diffusion into CSF, plasma accumulation of M6G may allow its more rapid diffusion into central nervous tissue, leading to the classical picture of respiratory depression [2, 3] .
This present study has confirmed that renal dysfunction does not impair the clearance of morphine in the anaesthetized patient, but does alter clearance of the glucuronide metabolites. The clinical importance of this may relate to the net effect of a single dose of morphine being the sum of the effects of the parent compound and its active metabolite(s). If this is the case, increased M6G concentrations may predispose to a greater net effect for any given dose of morphine.
